Perrigo Company plc(PRGO)
Pharmaceuticals
Specialty Pharma
| Filing Date | Insider | Type | 10b5-1 | Net Shares | Ownership change | Avg. Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2025-11-14 | Parker Geoffrey M. Director | Purchase | +7,500 | +75.95%17,375 | $14.18 | $106,350 | View SEC filing | |
| 2025-09-10 | Lennox Abigail EVP and CSO | Purchase | +1,255 | +100.00%1,255 | $22.41 | $28,125 | View SEC filing | |
| 2025-09-09 | Atkinson Charles EVP, General Counsel & Sec. | Purchase | +1,000 | +100.00%1,000 | $23.20 | $23,200 | View SEC filing | |
| 2025-08-22 | Willis Robert EVP & CHRO | Purchase | +1,488 | +3.68%41,939 | $24.10 | $35,858 | View SEC filing | |
| 2025-08-20 | Parker Geoffrey M. Director | Purchase | +4,375 | +79.55%9,875 | $22.97 | $100,497 | View SEC filing | |
| 2025-08-19 | Parker Geoffrey M. Director | Purchase | +4,375 | +15.13%33,287 | $22.97 | $100,497 | View SEC filing | |
| 2025-08-19 | Bezerra Eduardo Guarita EVP & Chief Financial Officer | Purchase | +3,000 | +6.53%48,949 | $22.74 | $68,207 | View SEC filing | |
| 2025-08-08 | Lockwood-Taylor Patrick CEO | Purchase | +4,460 | +5.48%85,812 | $22.37 | $99,766 | View SEC filing | |
| 2025-05-14 | Parker Geoffrey M. Director | Purchase | +3,500 | +17.27%23,762 | $27.10 | $94,850 | View SEC filing | |
| 2025-03-10 | Janish Ronald Craig EVP, Gbl Ops & SC & CTO | Sale | -7,800 | -18.81%33,666 | $27.44 | $214,032 | View SEC filing | |
| 2024-12-10 | KINDLER JEFFREY B Director | Sale | -17,598 | -76.49%5,409 | $28.27 | $497,495 | View SEC filing | |
| 2024-09-13 | Doyle Katherine C. Director | Sale | -8,954 | -59.84%6,009 | $27.30 | $244,444 | View SEC filing | |
| 2024-08-28 | Janish Ronald Craig EVP, Gbl Ops & SC & CTO | Sale | -13,000 | -38.74%20,553 | $29.40 | $382,246 | View SEC filing | |
| 2024-08-21 | Andersen Svend EVP & President CHCI | Sale | -34,983 | -30.28%80,553 | $27.69 | $968,560 | View SEC filing | |
| 2024-05-31 | Andersen Svend EVP & President CHCI | Purchase | +1,000 | +0.99%101,853 | $27.90 | $27,900 | View SEC filing | |
| 2024-03-07 | Ives Alison EVP & Chief Scientific Officer | Purchase | +2,490 | +18.27%16,122 | $27.26 | $67,877 | View SEC filing | |
| 2024-03-07 | Ives Alison EVP & Chief Scientific Officer | Purchase | +1,545 | +14.17%12,446 | $26.44 | $40,850 | View SEC filing | |
| 2024-03-07 | Ives Alison EVP & Chief Scientific Officer | Purchase | +2,040 | +23.02%10,901 | $29.34 | $59,854 | View SEC filing | |
| 2024-03-01 | Willis Robert EVP & CHRO | Purchase | +6,371 | +33.35%25,476 | $25.90 | $164,977 | View SEC filing | |
| 2024-02-29 | Lockwood-Taylor Patrick CEO | Purchase | +9,500 | +86.36%20,500 | $26.54 | $252,168 | View SEC filing | |
| 2023-11-27 | Willis Robert EVP & CHRO | Purchase | +5,550 | +40.94%19,105 | $31.01 | $172,106 | View SEC filing | |
| 2023-11-17 | Ives Alison EVP & Chief Scientific Officer | Purchase | +2,040 | +24.46%10,380 | $29.34 | $59,854 | View SEC filing | |
| 2023-11-15 | Bezerra Eduardo Guarita EVP & Chief Financial Officer | Purchase | +5,000 | +145.86%8,428 | $29.18 | $145,882 | View SEC filing | |
| 2023-11-14 | Lockwood-Taylor Patrick CEO | Purchase | +11,000 | +100.00%11,000 | $28.99 | $318,868 | View SEC filing | |
| 2023-06-14 | Parker Geoffrey M. Director | Purchase | +10,000 | +62.98%25,879 | $33.06 | $330,637 | View SEC filing |
1-25 of 124